CareDx To Acquire Transplant Hero Medication Management Application

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients.

The acquisition of Transplant Hero builds on AlloCare, the comprehensive CareDx mobile health app for managing the day-to-day health of patients before and after transplant. Transplant Hero strengthens CareDx’s focus on the transplant patient journey and adds to its growing digital portfolio which includes a robust suite of cloud-based solutions and software for transplant centers and dialysis providers.

Transplant Hero provides a smartphone app focused on helping transplant patients manage their medications through alarms and interactive logging of medication events. Medication management is especially important for transplant patients who must follow a regular regimen to protect against organ rejection. The number of pills and the complexity of the regimen often makes medication management a challenge. The app offers support to various types of organ recipients, including kidney, heart, lung, liver, pancreas, and small bowel.

“CareDx and Transplant Hero are both dedicated to improving outcomes for transplant patients,” said Reg Seeto, President and CEO, CareDx. “Transplant Hero’s easy-to-use interface and transplant focus allows us to expand into different organs. We will be able to leverage Transplant Hero’s well-established social media presence to augment AlloCare which has been built around patients from kidney transplant centers.”

“CareDx continues to make a difference in the lives of transplant patients and is a great fit for why Transplant Hero was originally founded. We are looking forward to working together to help improve the lives of individual transplant patients,” said Jay Graham, MD, MBA, FACS, Founder and CEO of Transplant Hero.

SourceCareDx

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."